AstraZeneca: lung cancer drug delays disease progression
(CercleFinance.com) - AstraZeneca said that its Imfinzi drug reduced the progression of lung cancer in a late-stage trial.
A Phase III trial in previously-untreated stage IV (metastatic) non-small cell lung cancer (NSCLC) met a primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival in patients treated with the combination of Imfinzi and a five standard-of-care platinum-based chemotherapy options vs. chemotherapy alone.
The trial, conducted in 153 centres across 18 countries, will continue to assess the additional primary endpoint of overall survival with data anticipated in 2020, AstraZeneca said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
A Phase III trial in previously-untreated stage IV (metastatic) non-small cell lung cancer (NSCLC) met a primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival in patients treated with the combination of Imfinzi and a five standard-of-care platinum-based chemotherapy options vs. chemotherapy alone.
The trial, conducted in 153 centres across 18 countries, will continue to assess the additional primary endpoint of overall survival with data anticipated in 2020, AstraZeneca said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.